TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03548350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthyKidz physical activity programme
Description: A 24 week physical activity intervention to promote fitness and wellbeing in primary schools
Study: NCT03438942

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid and iron supplementation
Description: Individuals with low level of blood folic acid and iron- will receive folic acid and iron supplementation daily, for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Individuals with proper level of blood folic acid and iron- will not receive folic acid and iron supplementation daily, for 3 months
Study: NCT02942121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LifeScience Technologies application
Description: Application for mobile devices. The app enables users to review educational videos about a surgery and recovery from a surgery from home. It also enables the user to track different metrics specific to the user's health.
Study: NCT04569929

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: (DLP)-printed photo-polymerizable PMMA Nextdent mandibular implant overdenture
Description: The bite registration records with their corresponding master casts were digitalized using an extra oral desktop 3D scanner (3shape D850) and then stored as standard triangulation language (STL) files (Figure 1). The STL files were then imported to Dental system PREMIUM3 design software (3Shape Dental System 2018) for model analysis, surveying and blocking out, designing full permanent denture bases, and for virtual teeth set-up following the recorded inter-arch space

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (DLP)-printed photo-polymerizable PMMA Nextdent mandibular implant overdenture
Description: The bite registration records with their corresponding master casts were digitalized using an extra oral desktop 3D scanner (3shape D850) and then stored as standard triangulation language (STL) files (Figure 1). The STL files were then imported to Dental system PREMIUM3 design software (3Shape Dental System 2018) for model analysis, surveying and blocking out, designing full permanent denture bases, and for virtual teeth set-up following the recorded inter-arch space
Study: NCT05201443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser
Description: Diode Laser is applied to one group as an adjunctive therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titanium curettes
Description: Non-surgical treatment with titanium curettes were administrated to both groups.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium curettes
Description: Non-surgical treatment with titanium curettes were administrated to both groups.
Study: NCT02849704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creon36™
Description: Creon36™ delayed-release capsules, a pancreatic enzyme preparation, is an FDA approved medication. Subjects with chronic pancreatitis (CP) will take Creon36™ for nine days, at a daily dose of 72,000 lipase units per meal (two capsules) and 36,000 units per snack (one capsule), with each capsule containing 36,000 lipase units. Subjects will take Creon36™ for three days prior to Visit 2, the day of Visit 2 and then for five days after the visit until they have completed stool collections.
Study: NCT03016468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral Remodulin (treprostinil) injection
Description: Remodulin will be provided in vial strengths of 1, 2.5, 5, and 10 mg/mL. Subjects will be admitted to the hospital and IV Remodulin will be initiated within 12 hours after the last dose of selexipag. Subjects will remain under observation in the inpatient setting for at least the first 72 hours of Remodulin administration. Subjects will be transitioned to an equivalent dose of SC Remodulin at discharge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Treprostinil
Description: Oral treprostinil will be provided as 0.125-, 0.25-, 1-, or 2.5-mg extended-release tablets. Oral treprostinil will be dosed three times daily with food.
Study: NCT00734656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutasteride + ethanol
Description: 4 mg dutasteride administered 2-4 days prior to ingestion of 0.8 mg/kg ethanol divided between three drinks consumed over 36 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo medication + ethanol
Description: placebo medication administered 2-4 days prior to ingestion of 0.8 gr/kg ethanol divided between three drinks consumed over 36 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutasteride + placebo alcohol
Description: 4 mg dutasteride administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo medication + placebo alcohol
Description: placebo medication administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes
Study: NCT03127761

Intervention type: OTHER
Intervention: Allogeneic Hematopoietic Stem Cell Transplant
Description: This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of matched autoHCT controls.
Study: NCT01453790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Specific Depression Education and Motivation
Description: Parent-specific written and verbal depression messages garnered from previous research were consolidated into a pamphlet and script, respectively. These are dispensed after randomization in the pediatric office. At two days, mothers in the experimental group receive a motivational telephone call.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Depression Education-Motivation
Description: General depression education messages were compiled and are delivered verbally (scripted) and written (JAMA Depression Patient Page) after randomization in the pediatric office. At 2 days, mothers in the comparison group receive an attention control telephone call.
Study: NCT01911793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stoma Tube
Description: Stoma tube will be inserted into stoma at the time of surgery for patients assigned to Stoma Tube group.
Study: NCT03664921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnitram Oral Tablet
Description: Administered three times daily for 28 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Administered three times daily for 28 consecutive days.
Study: NCT02707172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: handwashing with soap
Description: handwashing with soap by a standardized 6-step handwashing technique

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: handwashing with soap
Description: handwashing with soap by a standardized 6-step handwashing technique

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: handwashing with water
Description: handwashing with water by a standardized 6-step handwashing technique

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: handwashing with water
Description: handwashing with water by a standardized 6-step handwashing technique
Study: NCT04438720

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Release Nifedipine Tablets 30 mg (Adalat® GITS)
Description: The subjects randomly received single oral administration of extended release nifedipine tablets 30 mg.
Study: NCT01810523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative
Description: Narrative form as described above.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Blank piece of paper
Study: NCT04871399

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Right hemicolectomy (Non-CME)
Description: Transecting the Ileocolic Vein and Artery close to the Superior Mesenteric Vessels without clearing the superior mesenteric vein (SMV) from the adipose tissue. Transecting the Right Colic Vein and Artery and superior right colic vein (when present) peripherally. Transecting the Right branches of the Middle Colic Vein (MCV) and the Middle Colic Artery (MCA) peripherally, without clearing the main trunk of the MCV and the MCA. The Right Gastroepiploic Vein and artery are never transacted.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right hemicolectomy with CME+CVL
Description: Separation of the visceral fascia from the parietal fascia by sharp dissection leaving intact mesocolon coverage. Transecting the supplying vessels at their origin from the main vessels, particularly:~* The Ileocolic Vessels, The Right Colic Vessels,The superior right colic vein (when present), The Right branches of the Middle Colic Vein and of the Middle Colic Artery~* The MCV and MCA at their origin in case of cancer of the hepatic flexure or of the proximal third of the transverse colon, as well as The Right Gastroepiploic Vessels at their origin from the gastrocolic trunk of Henle (GCTH) and the gastroduodenal artery.~The SMV should be cleared from all adipose tissue all along its anterior surface until its intrapancreatic entrance.
Study: NCT02698709

Intervention type: OTHER
Intervention: Analysis of anterior and posterior corneal surfaces
Description: Corneal data obtained from a Scheimpflug-based topographer were converted to astigmatic vectors in accordance to the method proposed by Thibos

Intervention type: OTHER
Intervention: Analysis of anterior and posterior corneal surfaces
Description: Corneal data obtained from a Scheimpflug-based topographer were converted to astigmatic vectors in accordance to the method proposed by Thibos

Intervention type: OTHER
Intervention: Analysis of anterior and posterior corneal surfaces
Description: Corneal data obtained from a Scheimpflug-based topographer were converted to astigmatic vectors in accordance to the method proposed by Thibos
Study: NCT01716611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan
Description: 15 - 60 mg/day for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03917979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual GIM
Description: Participants are provided with a series of 10 individual GIM sessions, scheduled once every two weeks. Frequency may change if clinically indicated. Individual GIM sessions begin with a discussion of important issues related to the client's life and symptoms, forming a focus for the session. Then, the therapist provides suggestions to help the client become highly relaxed and focused in preparation for the music-listening portion of the session. The therapist plays specially-selected music from the Western classical tradition to match the client and the focus for the session, and engages in verbal dialogue with the client to help them explore their own internal imagery while listening to the music. After the music ends, the therapist and client engage in discussion about their imagery in metaphoric connection to their therapeutic process. This may include arts-based approaches to process the session. Sessions last approximately 90-120 minutes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist Control
Description: Participants complete an initial wait list period of 26 weeks, equivalent to the treatment and 6-week follow-up period for the experimental arm. They are then provided with four Group GIM sessions scheduled once per week. Group GIM sessions start with a group discussion about events or feelings from the week and issues related to depression and wellbeing. Then the therapist provides suggests to help the clients relax and focus in preparation for the music-listening period. Group members will explore a theme or issue related to therapy while focusing on whatever comes to them as the music is played. After the music, there will be a time to work with the imagery experienced during the music. This may be in the form of discussion or other art forms. The session ends with a discussion about gains and insights from the music and imagery. Sessions last 90-120 minutes.
Study: NCT01754766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-229666
Description: One drop of AGN-229666 into each eye on Day 1 and Day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-229666
Description: One drop of AGN-229666 into each eye on Day 1 and Day 15.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: vehicle of AGN-229666
Description: One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.
Study: NCT04248478

Intervention type: OTHER
Intervention: Eating Behaviours
Description: Patients' eating behaviour will be questioned with Three Factor Eating Questionnaire. The 18-item Three-Factor Eating Questionnaire is a scale that measures three domains of eating behavior: cognitive restraint , uncontrolled eating and emotional eating.

Intervention type: OTHER
Intervention: Eating Behaviours
Description: Patients' eating behaviour will be questioned with Three Factor Eating Questionnaire. The 18-item Three-Factor Eating Questionnaire is a scale that measures three domains of eating behavior: cognitive restraint , uncontrolled eating and emotional eating.

Intervention type: OTHER
Intervention: Health Status
Description: The effect of fibromyalgia on the daily life of the patients will be questioned with Fibromyalgia Impact Questionnaire (FIQ). The FIQ was developed from information gathered from patient reports, functional status instruments, and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue, and well-being over the past week.
Study: NCT01722279

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Study: NCT03843697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: An App for reminding patients to take their medication
Description: Open-label, single-center study, up to 20 adults (\>18) male and female with inflammatory bowel disease (chorn's disease, ulcerative colitis), unresponsive to biological drugs, will participate in a 4-week observation period during which no change in drugs is permitted. The patients will then begin 10-week treatment by taking their medications according to a semi-random schedule that is pre-set for them by the physician using the same drugs the patient is taking and only changing the dose and times of taking them each day while keeping the drugs within their therapeutic window.
Study: NCT03552523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas
Description: During this arm the subject will ONLY use our bionic pancreas device with an insulin only configuration using a rapid-acting insulin analog. Subjects will wear a continuous glucose monitoring device (the Dexcom G5) as part of the bionic pancreas, and use the study provided glucose meter.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Subject will wear a continuous glucose monitoring device (the Dexcom G5) and use the study provided glucose meter.. Subject will not change their prescribed home insulin therapy regimen during this arm whether that be an insulin pump or multiple daily injections.
Study: NCT03143738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous anesthesia of adductor canal
Description: After subarachnoid anesthesia, but before the beginning of surgery, a catheter will be implemented to the adductor canal and infusion of 5 mL/h of 0.2 % ropivacaine will be started.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous anesthesia of femoral nerve
Description: After subarachnoid anesthesia, but before the beginning of surgery, a catheter will be implemented next to the femoral nerve (below inguinal ligament) and infusion of 5 mL/h of 0.2 % ropivacaine will be started.
Study: NCT03286660

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Chair Rise Tests and short questionnaire
Description: Exercises consist on a Chair Rise Tests and short questionnaire It is a functional test evaluating the number of chair rise over a given time and / or frequency.~This test is combined with a questionnaire to collect quantitative and qualitative information:~* dyspnea and muscular fatigue at rest before the start of the test and at the end of the exercise~* Saturation at rest, and at the end of the exercise~* the number of total a chair rise
Study: NCT03585517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM23
Description: T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor
Study: NCT03039465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Trans-Esophageal Prosthesis
Description: This device is a biomedical grade silicon voice prosthesis with an inner esophageal flange, a stem and an outer tracheal flange. Insertion would be done through a modified 'romovac' inserter set / curved metal inserter (provided with the TEP) and an oesophagoscope in case of secondary insertion would be used. in patients with existing TEP puncture / who require a TEP change, on out-patient basis, the insertion would be done with a novel two-part inserter device (front loading)
Study: NCT04733625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: single injection of Vitamin D (200000 I.U
Study: NCT03143738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: Before the beginning of surgery all patients will be anesthetised with 0.5 % hyperbaric bupivacaine (Marcaine Heavy), 2.0 - 2.5 mL solution. Pencil point spinal needle will be used.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: Before the beginning of surgery all patients will be anesthetised with 0.5 % hyperbaric bupivacaine (Marcaine Heavy), 2.0 - 2.5 mL solution. Pencil point spinal needle will be used.
Study: NCT03995316

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment As Usual + MMB 2.0
Description: Women assigned to use MMB 2.0, along with NorthShore HealthSystem's well established usual care, will be guided by the program to move sequentially through 6 sessions, one of which becomes available for use each week, while interacting with engaging activities within each session along with recommended practice activities to encourage transfer of learning and skills to everyday routines. Content is presented using text, interactions, animations, and videos. MMB includes daily tracking and charting of mood and pleasant activities as well as online access to a library, covering a range of issues of concern to pregnant women and new mothers. Integrated text messages offer both motivational messages and links to access specific portions of session content in the MMB 2.0 program. The study coordinator will also provide up to 3 supportive coaching calls to each woman in the MMB 2.0 condition. These calls complement and thus are adjunctive to the MMB 2.0 program.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment As Usual Only
Description: NorthShore HealthSystem's treatment as usual, or usual care, has been in place since 2003. Screen positive women randomized to this condition will receive social work assessment by phone, followed by community mental health referral as indicated. Referrals will vary by need and may include psychotherapy, support groups, or psychiatry. Referrals will include consideration of geographic proximity, insurance, and acuity. Consistent with routine practice, NorthShore staff will document time spent during evaluation and in making specific referrals.
Study: NCT02871505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzathine Penicillin G

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzathine Penicillin G
Study: NCT00808002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 400 mg every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Raltegravir 400 mg every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc 300 mg every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir/Emtricitabine
Description: Tenofovir/Emtricitabine 300/200 mg every 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir/Emtricitabine
Description: Tenofovir/Emtricitabine 300/200 mg every 24 hours
Study: NCT02083289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-9054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Study: NCT01666093

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Angioplasty of the lower limbs vessels
Description: Standard revascularization techniques will be used in the study
Study: NCT04811144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG dental laser
Description: To treat Cavity, Sensitive Teeth, Abnormal Frenum Attachment and Peri-implantitis by using Er:YAG Dental Laser system which manufactured by LightMed Dental Technology Corp

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG dental laser
Description: To treat Cavity, Sensitive Teeth, Abnormal Frenum Attachment and Peri-implantitis by using Er:YAG Dental Laser system which manufactured by LightMed Dental Technology Corp

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG dental laser
Description: To treat Cavity, Sensitive Teeth, Abnormal Frenum Attachment and Peri-implantitis by using Er:YAG Dental Laser system which manufactured by LightMed Dental Technology Corp

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG dental laser
Description: To treat Cavity, Sensitive Teeth, Abnormal Frenum Attachment and Peri-implantitis by using Er:YAG Dental Laser system which manufactured by LightMed Dental Technology Corp
Study: NCT03999632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary modification with introduction of Mankai
Description: Substituting the standard high protein, low carbohydrate preoperative shake during the preoperative liquid diet with Wolffia Globosa (Mankai) shake consisting of 16 oz of skim milk + 1 frozen cube of Wolffia Globosa (Mankai) +/- sugar substitute.
Study: NCT03050190

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Therapeutic 4SCAR19 cells
Description: Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19
Study: NCT03239327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol